STAMBP and melanoma: When the cells were treated with BI-D1870, an inhibitor of RSK2 C-terminal kinase, in B16F10 melanoma cells, the cell darkness was strongly inhibited compared to co-treatment of α-MSH alone and α-MSH/UVA (Fig. 3A).